MRI in cancer diagnosis
MRI in cancer diagnosis is a research topic within Radiology, Nuclear Medicine and Imaging. Science Explorer counts 33k research works in it since 1951. 18.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the use of breast magnetic resonance imaging (MRI) in oncology, particularly in the context of cancer biomarkers, diagnostic accuracy for breast lesions, monitoring tumor response to neoadjuvant chemotherapy, and the application of diffusion-weighted and dynamic contrast-enhanced MRI for assessing perfusion and tumor characteristics. The research also explores the potential of breast MRI as a tool for predicting and monitoring treatment response in breast cancer patients.
- Breast MRI
- Diffusion-Weighted Imaging
- Dynamic Contrast-Enhanced MRI
- Cancer Biomarkers
- Breast Lesions
- Diagnostic Accuracy
- Neoadjuvant Chemotherapy
- Tumor Response
- Perfusion Imaging
- Magnetic Resonance Imaging
- Research works
- 33k fractional, since 1951
- In the world top 10%
- 5.9k per year above
- Top-10% rate
- 18.1% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -4% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead MRI in cancer diagnosis research?
By volume, China and the United States publish the most (1.4k and 1.1k works in 2022–2025).
By volume, 2022–2025
- 1 China 1.4k works
- 2 United States 1.1k works
- 3 Germany 303 works
- 4 Japan 279 works
- 5 Italy 211 works
- 6 United Kingdom 203 works
- 7 South Korea 179 works
- 8 India 176 works
- 9 Netherlands 131 works
- 10 France 129 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead MRI in cancer diagnosis research?
By volume in 2022–2025, Memorial Sloan Kettering Cancer Center publishes the most MRI in cancer diagnosis research, followed by Sun Yat-sen University and The University of Texas MD Anderson Cancer Center.
By volume, 2022–2025
- 1 Memorial Sloan Kettering Cancer CenterUnited States 30 works
- 2 Sun Yat-sen UniversityChina 30 works
- 3 The University of Texas MD Anderson Cancer CenterUnited States 30 works
- 4 Siemens Healthineers (Germany)Germany 23 works
- 5 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 22 works
- 6 Nanjing Medical UniversityChina 20 works
- 7 Harvard UniversityUnited States 19 works
- 8 Johns Hopkins UniversityUnited States 19 works
- 9 Stanford UniversityUnited States 19 works
- 10 Shanghai Jiao Tong UniversityChina 19 works
Who are the leading researchers in MRI in cancer diagnosis?
The most-cited researchers publishing on MRI in cancer diagnosis include Lawrence H. Schwartz, John C. Morris and Marcus E. Raichle.
- 1 Lawrence H. Schwartz United States 5.8k citations
- 2 John C. Morris United States 5.1k citations
- 3 Marcus E. Raichle United States 3.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is MRI in cancer diagnosis research done?
The largest centres of MRI in cancer diagnosis research in 2022–2025 are Shanghai (China), Beijing (China), Guangzhou (China) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Forchheim and Heidelberg.
Largest cities, 2022–2025
Where it is the local speciality
- ForchheimDE · 23.1 works195×
- HeidelbergDE · 36.7 works7.1×
Location quotient: how much more of its research is in MRI in cancer diagnosis than the world average.
Where is the best place to study MRI in cancer diagnosis?
Among universities, judged by research, Nanjing Medical University, Medical University of Vienna and Harvard University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Nanjing Medical UniversityChina | 53.6 | 19.1% | 7.7× | 20 | +50.4% |
| 2 | Medical University of ViennaAustria | 52.5 | 17.0% | 8.8× | 13 | +8.0% |
| 3 | Harvard UniversityUnited States | 50.8 | 28.2% | 3.0× | 19 | +24.7% |
| 4 | China Medical UniversityChina | 50.6 | 37.5% | 6.7× | 11 | -43.5% |
| 5 | Fujian Medical UniversityChina | 50.3 | 21.3% | 8.9× | 16 | -30.3% |
| 6 | University College LondonUnited Kingdom | 49.4 | 32.3% | 2.2× | 15 | +25.0% |
| 7 | Sun Yat-sen UniversityChina | 48.6 | 21.5% | 3.8× | 30 | -8.9% |
| 8 | Heidelberg UniversityGermany | 47.9 | 25.4% | 5.3× | 14 | -18.4% |
| 9 | Chinese University of Hong KongHong Kong | 46.5 | 35.0% | 2.8× | 10 | -34.3% |
| 10 | Medical College of WisconsinUnited States | 45.8 | 8.6% | 10.9× | 14 | +34.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is MRI in cancer diagnosis research growing?
Output in 2018–2022 was 4% lower than in 2013–2017, peaking in 2014. The fastest-growing topics are MRI in cancer diagnosis.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.